To date, experimental evidence for CAPE’s anti-angiogenic activity stems largely from non-ovarian cancer systems: CAPE has been shown to inhibit VEGF-induced VEGFR-2 tyrosine-phosphorylation in endothelial cells, thereby suppressing VEGF/VEGFR-2-dependent angiogenesis [96]. This evidence concerns the gene VEGFA and ovarian carcinoma.